AstraZeneca Results Presentation Deck
AstraZeneca in summary
Pipeline-driven transformation
Global presence
Balanced specialty and
primary-care franchises¹
Leading emerging markets
presence with R&D base
Strong pipeline
22 Phase III medicines and
significant lifecycle projects²
Advancing early- and
mid-stage pipeline
Improving financials
Ten blockbuster medicines2,3
Returned to durable
revenue and earnings growth
Focus on operating
leverage and cash flow
Innovative medicines in Oncology, Rare Diseases & BioPharmaceuticals4
Experienced and proven team
1. In H1 2021, medicines for use in speciality care, typically in the hospital setting (Oncology, Brilinta, Lokelma, roxadustat and Fasenra) comprised 51% of total revenue 2. Alexion to be included from next quarter 3. Last four quarters, excludes COVID-19 vaccine
4. Cardiovascular, Renal & Metabolism and Respiratory & Immunology.
4
36View entire presentation